Who expects Novartis India to focus on more targeted therapy-aligned acquisitions to boost growth in Tier 2-3 markets?

In their latest annual report, analysts predict a significant expansion of pharmaceutical company Novartis India Ltd's business through strategic and focused mergers.

• Option 1: Tier 1-focused buyers expect more than NIL will be doing this year
• Option 2: Nil has a narrow focus on therapy-aligned acquisitions